The New MiniMed Paradigm® REAL-Time Insulin Pump and Continuous Glucose Monitoring System

The World's First Integrated Insulin Pump System with Continuous Glucose Readings

MiniMed Paradigm REAL-Time

Now for the first time, continuous glucose monitoring is integrated with an insulin pump. This first-in-class system gives patients REAL access to glucose patterns so they can intervene more quickly while making it easier for you, the healthcare provider, to optimise their diabetes management. [1, 2, 3]

The system includes a continuous glucose sensor, a radio frequency transmitter, and the MiniMed Paradigm 522 or 722 insulin pump. It gives patients continuous glucose readings, trending, and alarms around the clock, and also includes special software that downloads valuable data from the insulin pump and glucose sensor for more in-depth insights into patient progress than a logbook alone. You and your patients will have the information you need to better detect and manage glycaemic excursions to reduce HbA1c levels [1, 2, 3] and related diabetes complications. [4, 5]

Useful for type 1 and type 2 patients

The components of the MiniMed Paradigm® REAL-Time Insulin Pump and Continuous Glucose Monitoring System can help all of your insulin-dependent patients.

Insulin pump therapy is especially helpful in cases like these:
  • Nocturnal and postprandial hypoglycaemia [6, 7]
  • Dawn phenonmenon [8, 9, 10]
  • Gastroparesis
  • Pregnancy
  • Pediatric patients as young as 1 year old [12]
  • LADA (latent autoimmune diabetes in adults) patients misdiagnosed as Type 2 [13]
REAL improvement for type 1 diabetes patients
  • Reduces HbA1c levels: Insulin pump therapy helped achieve the HbA1c target of 7% or less in 50% of patients versus only 12% of patients using MDI with long-acting insulin (glargine)[ 14]
  • Reduces complication risks: Each 1% reduction in HbA1c reduces the risk of long-term complications like eye, nerve, kidney and heart disease by 15% to 30% [15]

Insulin pump therapy reduces hba1c levels vs. mdi with long-acting insulin (glargine) [14]
Glucose chart

REAL improvement for type 2 patients
  • Preferred by patients: Type 2 diabetes patients preferred an insulin pump to injections when initiating insulin therapy [16]
  • Improves satisfaction and adherence: Overall, Type 2 diabetes patients using insulin pump therapy are happier with the treatment than those on injections, which leads to better adherence [16]
REAL reduction in hypoglycaemia
  • Reduces severe lows: Insulin pump therapy is consistently associated with fewer cases of severe hypoglycaemia [17, 18]
  • Insulin pump therapy patients showed a 73.8% reduction in the frequency of severe hypoglycaemia vs. MDI patients [17]
  • Reduces overnight lows: Insulin pump therapy patients spent only 12.8% of time overnight at BG < 70 mg/dL vs. 34.7% of time overnight spent by MDI with long-acting insulin (glargine) patients [19]

Insulin pump therapy reduces the risk of severe lows vs. mdi [17]

Insulin pump chart

REAL reduction in morning hyperglycaemia
  • Affects 89% of patients: Dawn phenomenon is a morning rise in glucose levels affecting up to 89% of Type 1 diabetes patients [20]
  • Stabilises morning glucose levels: The variable basal rate associated with an insulin pump helps to improve morning glucose stability [21, 22]
  • Works better than long-acting insulin: The fixed basal rate associated with long-acting insulin is not flexible enough to properly manage a morning glucose rise
REAL management of gastroparesis
  • Adjusts to slower digestion: The MiniMed Paradigm 522 or 722 insulin pump offers exclusive programming options that daily injections cannot. Additionally, the faster-acting insulin used in insulin pump therapy has more predictable insulin action [23] versus long-acting insulin (glargine) [24]
  • This more predictable absorption rate helps gastroparesis patients to better match insulin delivery to their body's slower digestion [25, 26]
  • Insulin pump therapy helps better manage hypoglycaemia caused by post-injection rise in insulin levels, as well as hyperglycaemia occurring during digestion once insulin levels have declined [25, 26]
REAL improvement for pregnant patients
  • Better matches fluctuating insulin requirements: Insulin pump therapy addresses the fluctuations occurring during pregnancy27 better than MDI, due to programmability and more predictable insulin action [28]
  • Reduces HbA1c levels in pregnant Type 1 patients: Post partum HbA1c levels averaged 7.2% in insulin pump users vs. 9.1% in those using MDI [29]
  • Reduces the risk of severe adverse outcomes: Higher HbA1c levels before and during pregnancy, among other factors, are associated with severe adverse outcomes [30]
REAL benefits for lada patients
"Type 1.5" LADA (latent autoimmune diabetes in adults) patients have characteristics similar to Type 1 diabetes patients but may be misdiagnosed as Type 2. [31]

  • Improves clinical outcomes: Insulin pump therapy has proven beneficial for Type 1 diabetes patients, and a diagnosis of Type 1 may be more appropriate for LADA patients than a Type 2 diagnosis
  • Earlier diagnosis can drive them to intensive management including insulin pump therapy
  • Insulin pump therapy reduces hypoglycaemia and HbA1c levels in Type 1 diabetes patients vs. MDI [32, 33]
  1. Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Research and Clin Practice. 1999;46:183-90.
  2. Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycaemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care. 2001;24(12):2030.
  3. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111(5 Pt 1):933-8.
  4. American Diabetes Association: Standards of Medical Care for Patients with Diabetes Mellitus. Diabetes Care. 2002;25(1):S33-49.
  5. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA. 1997;277(5):374-5.
  6. Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. Endocr Pract. 2002;8:401-5.
  7. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycaemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996;19(4):324-7.
  8. Koivisto VA, Yki-Jarvinen H, Helve E, et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes. 1986;35(1):78-82.
  9. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005;11(1):55-64.
  10. Perriello G, De Feo P, Torlone E, et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia. 1991;34(1):21-8.
  11. Gabbe SG, Holing E, Temple P, et al. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol. 2000;182(6):1283-91.
  12. Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics. 2004;114(6):1601-5.
  13. Schernthaner G, Hink S, Kopp HP, et al. Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes). Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S94-108.
  14. Doyle (Boland) E. A randomised, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:1554-8.
  15. American Diabetes Association: Standards of Medical Care for Patients with Diabetes Mellitus. Diabetes Care. 2002;25(1):S33-49.
  16. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomised parallel-group, 24-week study. Diabetes Care. 2003:26(9):2598-603.
  17. Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. Endocr Pract. 2002;8:401-5.
  18. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycaemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996;19(4):324-7.
  19. Armstrong D, King AB. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. Diabetes Care. 2003;26(4):1322.
  20. Perriello G, De Feo P, Torlone E, et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia. 1991;34(1):21-8.
  21. Koivisto VA, Yki-Jarvinen H, Helve E, et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes. 1986;35(1):78-82.
  22. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005;11:55-64.
  23. Lauritzen T, Pramming S, Deckert T, et al. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia. 1983;24(5):326-9.
  24. Scholtz HE, van Niekerk N, Mayer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 (glargine-Lantus) compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Abstract 0882. Poster Event D: 1999, Brussels, Belgium.
  25. Cucchiara S, Franzese A, Salvia G, et al. Gastric emptying delay and gastric electrical derangement in IDDM. Diabetes Care. 1998;21(3):438-43.
  26. Tanenberg RJ, Pfeifer MA. Continuous glucose monitoring system: a new approach to the diagnosis of diabetic gastroparesis. Diabetes Technol Ther. 2000;2(Suppl 1):S73-80.
  27. ADA Clinical Education Series: Medical Management of Pregnancy Complicated by Diabetes. 2000;91-3.
  28. Lauritzen T, Pramming S, Deckert T, et al. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia. 1983;24(5):326-9.
  29. Gabbe SG, Holing E, Temple P, et al.Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol. 2000;182(6):1283-91.
  30. Schernthaner G, Hink S, Kopp HP, et al. Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes). Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S94-108.
  31. Doyle (Boland) E. A randomised, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:1554-8.
  32. Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. Endocr Pract. 2002;8:401-5.